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ABSTRACT 
 
Typical reverse genetics systems for generating influenza viruses require the insertion of each genome 
segments by DNA ligation into vectors for genome synthesis and expression. Herein is described the 
construction and use of a novel pair of plasmid vectors for cloning all eight genome segments of influenza A 
virus by homologous recombination for influenza virus reverse genetics. Plasmids, pLLBA and pLLBG, 
were constructed to possess opposing RNA polymerase I and RNA polymerase II transcription units for 
generating influenza genomic and messenger RNAs, respectively. In addition these promoters flanked a 
recombination cassette which comprised the conserved 5’ (13bp) and 3’ (12bp) terminal promoters of 
influenza virus. These vectors differed due to the presence of an A or a G (plus sense) to correspond to 
differences at nucleotide position 4 among negative-sense influenza virus promoters. The cloning approach 
involved homologous recombination of each influenza gene segment and the appropriate linearized pLLBA 
or pLLBG vectors in E. coli. Direct cloning by recombination was simpler and faster than conventional 
restriction digestion and ligation methods. This new vector system was successfully used to clone and rescue 
various influenza viruses and thus has the potential to promote the rapid analysis and vaccine development of 
novel influenza strains. 
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INTRODUCTION 
 
Reverse genetics methods have become essential for the 
genetic manipulation of influenza viral genomes in both 
basic and applied research (Neumann and Kawaoka, 2001; 
Subbarao and Katz, 2004; Marsh and Tannock, 2005; 
Kash et al 2006, Palese, 2006; Horimoto and Kawaoka 
2006). Previously described reverse genetics systems for 
the generation of influenza virus from cloned genes 
include the 8-plasmid, 12-plasmid, and recently a 3-plamid 
system (Neumann et al, 1999; Neumann and Kawaoka, 
2001; Neumann et al, 2005) with the 8- and 12-plasmid 
systems being the most widely used. The 8-plasmid 
system consists of each of the 8 genome segments under 
control of the RNA polymerase I promoter and terminator 
transcription units that function to generate genomic sets 
of negative sense viral RNA. This transcription unit is 
further nested within an opposing RNA polymerase II 
promoter and a polyadenylation signal sequence, that 
simultaneously functions to generate synthetic influenza 
mRNA from the same cDNA templates. Translation of 
viral proteins functions to produce infectious virus from  
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the viral genome (Neumann and Kawaoka, 2001). In the 
traditional reverse genetics systems, restriction 
endonuclease enzyme cleavage and DNA ligation are used 
to clone each influenza virus genome segment into 
expression vectors. This cloning process is not only time-
consuming but is also prone to complications due to the 
presence of restriction endonuclease cleavage sites within 
the genome segments of some influenza strains that 
prevents the cloning of full length copies of genome 
segments. Cloning such genome segments that possess 
restriction sites used for cloning necessitates the use of 
alternative cloning and/or mutagenesis strategies. 
 
Homologous recombination involves a process of 
breakage and reunion in regions of identical DNA 
sequences between 2 DNA molecules to result in new 
combinations of genetic material (Watt et al, 1985). The 
process of genetic engineering by recombination is 
increasingly being applied to high-throughput cloning 
applications and has been termed recombineering 
(Copeland et al, 2001; Sawitzke et al, 2007). We now 
describe the construction of a new pair of vectors for 
reverse genetics of influenza virus that are designed for 
homologous recombination with influenza virus genome 
segments. The pLLBA and pLLBG plasmid vectors were 
constructed using component DNA fragments amplified 
by PCR that were recombined by using homologous 
recombination throughout the construction process. This 
approach avoided the requirement for unique restriction 
sites between plasmid components for restriction enzyme 
digestion and ligation and both simplified and shortened 
the construction process. 
 
The new reverse genetics vectors consist of three nested 
transcription units composed of opposing RNA 
polymerase I and II, DNA depended RNA polymerase 
promoters and terminators, for expressing viral and 
mRNA surrounding an influenza virus recombination 
cassette. The influenza recombination cassette consisted 
of both plus and minus strand influenza virus RNA 
dependent RNA polymerase promoters, separated by a 
StuI restriction site that was nested between the RNA 
polymerase I and II promoters. These vectors provided a 
means of cloning of all 8 influenza virus genome 
segments via recombination in E. coli, and that 
functioned to provide the synthesis of the negative-sense 
viral RNA and positive-sense mRNA from the same 
cDNA template in 293T cells. Using this system, the 
genomes of three influenza virus subtypes were cloned 
into the newly constructed vectors by recombination and 
were subsequently used to generate recombinant and re-
assortant influenza virus strains. 
 
MATERIALS AND METHODS 
 
Cells, viruses and RT-PCR 
293T human embryonic kidney cells and Madin-Darby 
canine kidney cells (MDCK) were maintained in DMEM 
supplemented with 10% (v/v) fetal calf serum (FCS), 
Penicillin (100U/ml), and Streptomycin (100µg/ml). All 
cells were maintained at 37°C in a 5% (v/v) CO2 
atmosphere. Influenza viruses A/Duck/Northern 
China/61/07 (H5N1), and A/Duck/Memphis/546/74 
(H11N9) were propagated in 10-day old embryonated 
eggs. The A/WSN/33 (H1N1) genome was obtained from 
pHH21 plasmids, which were maintained in the laboratory 
of Dr Earl Brown. Viral RNA was extracted from 200 µl 
volumes of allantoic fluid using the Promega viral RNA 
mini kit (USA). Influenza cDNA were subsequently 
prepared using a universal plus sense primer mixture U12 
5’GGGGAGCAAAAGCAGG plus 5’GGGGAGCGAAA 
GCAGG, and reverse transcription was performed in a 
reaction mixture containing 14µl RNA, 40pM primer, 
20mM of each dNTP, 40U RNasin, 200U Murine 
Leukemia reverse transcriptase (Promega) in a total 
volume of 20µl, then incubate at 37°C for 1hr. Each 
influenza virus segment was amplified from the cDNA 
mixture for each of the 3 virus subtypes by PCR using the 
appropriate segment specific primers (Table 1). The PCR 
reactions were carried out in a final volume of 25µl that 
contained 4µl cDNA, 0.25mM dNTP, 2.5µl 10x PCR 
buffer, 2.5U Pfu DNA polymerase (Promega) and 10pM 
of each oligonucleotide primer.  For PCR the samples 
were heated for 4min at 94°C, followed by 30 cycles of 
94°C for 30sec, annealing at 55°C for 30sec and 
elongation at 72°C for 6min, followed by single 10min 
incubation at 72°C to extend incomplete templates. PCR 
products were purified by agarose gel electrophoresis and 
eluted into water using the QIAgen Gel Elution kit 
(Qiagen).  
 
Construction of a pair of influenza reverse genetics 
vectors by recombinational cloning 
 
Construction of a minimal protein expression plasmid 
Firstly, a protein express vector was constructed by 
recombinational cloning. Two pairs of primers were 
designed to amplify the necessary regions from 
pCDNA3.0 (Invitrogen) and pIRES-EGFP (Invitrogen) for 
a complete but minimal protein expression vector. The 
primer set A (Primer A-plus 5'GAATTCTGCAGATATC 
CTCGAGCATGCATCTAG3'; Primer A-negative 5'TGTT 
CTTTCCTGCGCCGCTACAGGGCGCGTGG3') was 
used for amplifying the ampicillin resistance gene, the 
pBR322  E. coli origin of replication and the human 
cytomegalovirus (CMV) immediate early promoter of the 
pCDNA3.0 vector (Invitrogen).  Primer set B (Primer B-
plus 5'TGTAGCGGCGCAGGAAAGAACATGTGAGCA 
AA3'; Primer B-negative 5'CTCGAGGATATCTGCA 
GAATTCCAGCACAC3') was designed to amplify the 
bovine growth hormone (BGH) and the polyadenylation 
signal site from the pIRES-EGFP vector (Invitrogen). To 
promote site-directed recombination, the plus sense primer 
A and negative sense primer B had 22bp extensions of 
identical sequence at their 5’ ends (regions of homology 
are underlined). Similarly 22bp homology regions were 
designed into the termini of the negative sense A and plus 
sense primer B. 
 
PCR of plasmid DNA employed 2.5U of Pfu DNA 
polymerase (Promega), 10ng of pCDNA3.0 or pIRES-
EGFP, 2.5µl 10xPCR buffer, 5mM dNTPS, 10pM of each 
oligonucleotide primer in a 25µl reaction. The PCR 
reaction mixture was heated for 5min at 94°C, followed by 
30 cycles of 94°C for 30sec, annealing at 55°C for 30sec 
and elongation at 72°C for 4min, followed by one 10min 
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Table 1. Specific PCR primers for each genome segments of A/Duck/Northern China/61/07(H5N1), A/WSN/1933 (H1N1), and 
A/Duck/Memphis/546/74 (H11N9). 
 
Genome segment/virus 
aUF/G- and 
bUF/A-   
forward primer sequences 
cUR- reverse primer sequence 
PB2/H5N1 
PB2/H1N1 
PB2/H11N9 
UF/G-TCAAATATATTC 
UF/G-TCAATTATATTC 
UF/G-TCAAATATATTC 
UR-TCGTTTTTAAAC 
UR-TCGTTTTTAAAC 
UR-TCGTTTTTAAAC 
PB1/H5N1 
PB1/H1N1 
PB1/H11N9 
UF/G-CAAACCATTTGA 
UF/G-CAAACCATTTGA 
UF/G-CAAACCATTTGA 
UR-CATTTTTTCAC 
UR-CATTTTTTC 
UR-CATTTTTTC 
PA/H5N1 
PA/H1N1 
PA/H11N9 
UF/G-TACTGATCC 
UF/G-TACTGATCC 
UF/G-TACTGATCC 
UR-TACTTTTTTGG 
UR-TACTTTTTTGG 
UR-TACTTTTTTG 
HA/H5N1 
HA/H1N1 
HA/H11N9 
UF/A-GGTTCAATC 
UF/A-GGAAAAT 
UF/A-GGAAATATC 
UR-GTGTTTTTAAC 
UR-GTGTTTTTC 
UR-GTGTTTTTACTGCA 
NP/H5N1 
NP/H1N1 
NP/H11N9 
UF/A-GTAGATAATC 
UF/A-GTAGATAATC 
UF/A-GTAGATAATC 
UR-GTATTTTTC 
UR-GTATTTTTC 
UR-GTATTTTTC 
NA/H5N1 
NA/H1N1 
NA/H11N9 
UF/A-AGTTCAAAATG 
UF/A-AGTTTAAAATG 
UF/A-GTCAAGATGA 
UR-AGTTTTTTG 
UR-AGTTTTTTG 
UR-GTCTTTTTTC 
M1,2/H5N1 
M1,2/H1N1 
M1,2/H11N9 
UF/A-TAGATGTTG 
UF/A-TAGATATTG 
UF/A-TAGATGTTG 
UR-TAGTTTTTTAC 
UR-TAGTTTTTTAC 
UR-TAGTTTTTTAC 
NS 1,2/H5N1 
NS 1,2/H1N1 
NS 1,2/H11N9 
UF/A- GTGACAAAAAC 
UF/A-GTGACAAA 
UF/A-GTGACAAA  
UR-GTGTTTTTTATC 
UR-GTGTTTTTTATC 
UR-GTGTTTTTTAGT  
 
Notes: (a) Universal forward (G): UF/G = GGGGAGCGAAAGCAGG 
(b) Universal forward (A): UF/A = GGGGAGCAAAAGCAGG 
(c) Universal reverse: UR = GGTTATTAGTAGAAACAAGG 
 
 
incubation at 72°C to extend incomplete templates. PCR 
products were treated with 10U of DpnI for 1hr to digest 
the template DNA and purified by gel electrophoresis and 
elution into water using the QIAgen Gel Elution kit 
(Qiagen).  
 
To perform recombinational cloning, the BGH-polyA gene 
and the Ampicillin gene-pBR322 origin-CMV promoter 
PCR products were mixed together (200ng:50ng) and 
transformed into competent DHF5α E.  coli cells where 
the two sequences recombined via site directed 
homologous recombination into an intact circular vector 
(Figure 1). The sequence of an isolated ampicillin resistant 
colony was determined to be a recombinant plasmid, 
designated pHP and shown to be free of unwanted 
mutations after sequencing using a commercial sequencing 
service (ShangHai Sangon Ltd). 
 
Production of bidirectional influenza reverse genetics 
plasmids 
The RNA polymerase I promoter and terminator elements 
and influenza recombination cassettes were derived from 
pHH21A and pHH21G plamids (maintained in the 
laboratory of Dr EG Brown) and inserted between the 
RNA polymerase II promoter and BGH-polyA signal site 
of the pHP plasmid using the recombinational strategy 
described above. Therefore two primer sets, C and D, were 
designed for amplifying the complete pHP and the RNA 
polymerase I plus influenza recombination units, 
respectively. The following sequences were synthesized 
for primer sets C and D: Primer C-plus 5’ACCCAAG 
CTTCCGGAGTACTGGTCGACCTCC3'; primer C-
negative: 5'ATGCTCGAGGCCGGGAGGGCGTCCCCG 
GC3'; primer D-plus 5'AGTACTCCGGAAGCTTGG 
GTCTCCCTATAG3'; and primer D-negative 5'GCCCTC 
CCGGCCTCGAGCATCATCTAGAGG3'. The termini of 
the two pairs of primers had complementary sequences for 
insertion via recombination (regions of homology are 
underlined). 
 
The RNA polymerase I promoter and terminator elements 
flanking the influenza minus and plus stranded influenza 
promoter sets, that possessed either an A or G at position 4 
of the minus sense promoter, were cloned into the 
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Figure 1. The construction strategy of the minimal protein 
expressing plasmid, pHP vector, using homologous 
recombination. The BGH-polyA signal was recombined with the 
homologous termini of DNA that possessed the ampicillin gene-
pBR322 origin of replication-CMV promoter into a single vector 
by homologous recombination after transfection into E. coli. 
 
 
 
previously described protein expressing plasmid, pHP 
vector. This was achieved by transformation of competent 
DHF5α with a mixture of linear PCR products derived 
from the pHP and pHH21A or pHH21G plasmids to 
generate plasmids pLLBA and pLLBG, respectively. For 
use in recombinational cloning the pLLBA and pLLBG   
plasmids were linearized by digestion with StuI using 
10μg of plasmid DNA and 50U of StuI in a 100µl reaction 
volume with incubation at 37°C for 2 hr before agarose gel 
purification using the QIAquick Gel Elution kit (Qiagen).  
 
Recombinational cloning of influenza genomes 
Each of the 8 genome segments of three influenza viruses, 
A/Duck/Memphis/546/74 (H11N9), A/WSN/33 (H1N1) 
and A/Duck/Northern China/61/07 (H5N1) were 
amplified by PCR using appropriate primers (see Table 1) 
such that they possessed terminal complementarity with 
the linearized pLLBA and pLLBG vectors. Thus PCR 
products of all 8 genome segments of each virus were 
cloned into the appropriate vector by recombinational 
cloning in E. coli. According to the corresponding 
identities of the 4th base pair from the terminus of the 
negative sense influenza virus promoter the PB2, PB1, 
and PA segments were cloned into the pLLBG vector, and 
the HA, NA, NP, M1/M2, NS1/NS2 segments were 
cloned into pLLBA, where the two plasmids possessed a 
G or A, respectively. Insertion of influenza virus genome 
segments into these plasmid vectors was achieved by 
using a mixture of 200ng of cDNA and 50ng linearized 
vector for transformation into competent DHF5α cells. 
Colony PCR was used to screen the ampicillin resistant 
colonies using appropriate primers (Table 1). PCR 
positive clones were sequenced to assure that plasmids 
were inserted in the correct orientation and without 
unwanted mutations. 
 
Generation of recombinant influenza virus from plasmids 
To rescue virus from plasmids, 293T cells were 
transfected with genomic sets of 8 plasmids using cationic 
lipid transfection reagent, Lipofectin 2000 (LP2000), 
according to the manufacturer’s instructions. Briefly, 
genomic sets of 8 DNA plasmids (1μg of each segment 
except PA for which 0.1μg was used) and LP2000 were 
mixed in Opti-MEM, incubated at room temperature for 
20min, and then added to the cells, 6hr later, the DNA-
LP2000 mixture was replaced by Opti-MEM (Gibco) 
containing 2.5μg/ml trypsin. Forty-eight hours post- 
transfection, the culture supernatant was inoculated into 
10-day-old eggs to amplify the rescued viruses. 
 
To compare the efficiency of the simplified eight plasmid 
versus the 12 plasmid reverse genetics systems, virus 
rescue was also compared for a mixture of the 8 pLLB-
WSN-PB2, -PB1, -PA, -HA, -NP, -NA, -M, -NS plasmids 
versus the 8 corresponding pHH21 plasmids plus the 4 
polymerase expressing plasmids (pCDNA-WSN-PB2, 
PB1, PA, NP) in 293T cells. Virus yields were determined 
at 48hr post-transfection, by titration of the 50% tissue-
culture infectious dose (TCID50) in MDCK cells as 
previously described (Brown, 1990). 
 
RESULTS AND DISCUSSION 
 
Homologous recombination plays important roles in DNA 
replication and repair, and the promotion of genetic 
diversity in eukaryotic and prokaryotic organisms (Muyrers 
et al, 1999 and 2000; Yu et al, 2000; Ellis et al, 2001). The 
principles of homologous recombination have also been 
widely used in gene therapy and genetic engineering, 
referred to as recombineering (Yu et al, 2003; Amos et al, 
2004; Datta et al 2006; Berrow et al, 2007; Chan et al, 
2007). Here, we used recombinational cloning in influenza 
virus reverse genetics by constructing a pair of vectors that 
could recombine with influenza virus genomic cDNA 
strands in E. coli. Recombination was mediated by short 
terminal homologies engineered into each DNA molecule 
(15-19bp) that were then joined in transformed E. coli. 
Cloning via recombination in E. coli constitutes a simple 
method of engineering DNA that removes the need for 
restriction and ligation steps and thus both simplifies and 
shortens the cloning process relative to traditional cloning 
methods. Importantly, recombination method avoids the 
need for modified cloning strategies for influenza genome 
segments that possess internal restriction enzyme cleavage 
sites that prevents their cloning using traditional restriction 
enzyme digestion and ligation procedures. 
 
The pHP, pLLBA and pLLBG plasmids were constructed 
by recombination as described in Materials and Methods 
using the strategy outlined in Figures 1, 2 and 3. The 
pLLBA and pLLBG vectors  possessed  an  influenza virus   
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Figure 2. Construction strategy for generating the pLLBA  and  
pLLBG  vectors by homologous recombination. The RNA 
polymerase I (A/G) transcription units that flanked the influenza 
recombination cassettes composed of influenza virus promoters, 
were cloned between the RNA polymerase II promoter and the 
terminator of the linearized pHP vector, respectively, by 
homologous recombination. 
 
 
recombination cassette nested between RNA polymerase I 
promoters and terminators that were further nested within 
an opposing RNA polymerase II promoter and 
polyadenylation signal sequence. The RNA polymerase I 
transcription units of the pLLBA and pLLBG plasmids 
were derived from the pHH21A and pHH21G vectors that 
possessed a further nested set of influenza virus plus and 
minus sense promoters for RNA dependent viral 
replication of the viral complementary RNA strand and 
viral genomic RNA strands respectively (that constituted 
the influenza recombination cassette). This cassette 
consisted of the minus sense influenza virus promoter; 
nucleotides 1-13, AGTAGAAACAAGG, and both of the 
viral plus strand promoters (plus sense nucleotides1-12: 
AGCAAAAGCAGG or AGCGAAAGCAGG); inserted 
between the human RNA polymerase I promoter and 
mouse polymerase I terminators (Figures 2 and 3). Thus 
the resulting pLLBA and pLLBG plasmids were 3337bp in 
length and possessed influenza recombination cassettes 
that differed at the 4th position of the constituent negative 
sense influenza virus promoter; possessing an A or G 
respectively (plus sense nucleotides). The junction of the 
two influenza virus promoters formed a “natural” StuI 
cleavage site, AGGCCT  (Figure 3).   The   plasmids  were 
 
 
 
Figure 3.  Influenza virus genome cloning strategy by using the 
recombineering pLLBA and pLLBG plasmid vectors. The 
location and nature of the promoter components of the influenza 
recombination cassette is shown for the pLLBA and pLLBG 
vectors that differ by a single nucleotide at position 4 of the plus 
strand indicated for pLLBA and shown in parenthesis for the 
pLLBG sequence.  The plasmids were linearized with StuI, and 
mixed with the appropriate cDNA before transformation of 
competent E. coli. The cDNA recombined into circular plasmid 
within the regions of terminal complementarity to introduce virus 
genome segments between the start and stop sites of the RNA 
polymerase I promoter and terminator. The opposing RNA 
polymerase II promoter acts to generate plus sense mRNA form 
each genome segment.  
 
 
linearized by digestion with StuI to cleave at the junction 
point of the 2 promoters, and gel purified in order to 
generate vectors for recombination with each viral PCR 
products. Insertion of influenza genome segments was 
achieved by recombination with the terminal influenza 
promoters of linearized pLLBA and pLLBG vectors. The 
cloning of each influenza genome segments into these 
vectors allowed the synthesis of both the negative-sense 
viral RNA and positive-sense mRNA from the same 
cDNA template when introduced into 293T cells. 
 
The primers sets listed in Table 1 were effective at 
amplifying individual genome segments of the three 
influenza viruses H1N1, H11N9, H5N1. The PCR products 
of each genome segment were cloned into the recombina-
tional vectors by homologous recombination in competent 
DHF5α cells. The complete genomes of three influenza 
viruses were cloned into the appropriate pLLBA and 
pLLBG vectors with high cloning efficiency that ranged 
from 20-100% for each genome segment (Table 2). 
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Table 2. Cloning Efficiency of viral genome segments of A/Duck/Northern China/61/07 (H5N1), A/WSN/1933 (H1N1), and 
A/Duck/Memphis/546/74 (H11N9) into pLLBA and pLLBG vectors. 
 
 
Segments 
Positive clones/All screened clones 
H1N1 H5N1  H11N9 
PB2  4/5 (80 %)  2/10 (20 %)  1/5 (20 %) 
PB1  5/5 (100 %)  2/10(20 %)  2/5 (40 %) 
PA  4/5 (80 %)  3/10(30 %)  4/5 (80 %) 
HA  4/5 (80 %)  5/10(50 %)  3/5 (60 %) 
NP  4/5 (80 %)  6/10(60 %)  2/5 (40 %) 
NA  3/5 (60 %)  4/10(40 %)  3/5 (60 %) 
M  5/5 (100 %)  8/10(80 %)  4/5 (80 %) 
NS  2/5 (40 %)  5/10(50 %)  2/5 (40%) 
 
 
 
In addition, the genomes of other avian H9N2, swine 
H3N2, and swine H1N1 viruses were cloned into the 
pLLB vectors with high efficiency in our laboratories 
(data not shown). Our data suggests that influenza virus 
reverse genetics method was simpler, faster and more 
efficient than conventional approaches. High cloning 
efficiency required the use of sufficient amounts of PCR 
product at the appropriate ratio to linearized-vector 
(~200ng:50ng). All genes that were inserted in the 
pLLBA or pLLBG vectors were sequenced to show that 
all viral genome segments were inserted in the correct 
orientation without any mutations relative to the parental 
sequences, and thus were ready for use in virus rescue. 
The vector and primer sets were also compatible with the 
design features of the commercial In-Fusion
TM DNA 
cloning system (Clontech Laboratories Inc, CA) that can 
be used to further increase cloning efficiency and that 
would allow smaller amounts of plasmids and inserts to 
be used for cloning by recombination (Berrow et al, 
2007). 
 
A number of recombinant viruses, including A/Duck/ 
Memphis/546/74 (H11N9), A/WSN/33(H1N1) and 
A/Duck/Northern China/61/07 (H5N1), as well as several 
reassortant viruses, including H5N9, H1N9, and H11N1, 
were successfully rescued using genome segments cloned 
into the pLLBA and pLLBG vectors for recombination. 
The subtypes of each virus and reassortants were 
determined by HI and NI assay using subtype-specific 
antiserum (Liu et al, 2005). The 8-plasmid system was less 
complex than the 12-plasmid system as virus rescue only 
required the transfection of cells with 8 instead of 12 
plasmids. We compared the efficiency of virus rescue 
using the previously constructed A/WSN/33 12 plasmid 
system and the newly constructed 8-plasmid A/WSN/33 
system. The yield of infectious WSN/33 virus rescued at 
48hr post-transfection using the 8WSN- pLLB-PB2, PB1, 
PA, HA, NP, NA, M, NS, plasmids was 104.3±0.3 
TCID50/ml that was significantly higher than the titer of 
WSN/33 virus obtained in experiments in which cells were 
transfected with the 12-plasmid system. The 12-plasmid 
system consisted of eight RNA polymerase I-driven 
plasmids for the transcription of the WSN influenza 
vRNAs, four protein expressing plasmids for the synthesis 
of NP and three RNA polymerase subunits that yielded 
103.15±0.35 TCID50/ml. These data showed that the 
pLLBA/G 8-plasmid system was >10 fold more efficient 
than the 12-plasmid system for generating the same 
recombinant A/WSN/33 virus in 293T cells. This may be 
due to the increased efficiency of introducing 8 as 
compared to 12 plasmids into individual cells. 
 
In the present study, recombinational cloning was also 
used to construct all three vectors, pHP, pLLBA and 
pLLBG. The vectors were designed to be minimal 
constructs of small size and thus are expected to be more 
genetically stable that larger plasmids described for use in 
other conventional influenza reverse genetics plasmid 
systems. Moreover, we constructed various other kinds of 
vectors by this recombinational cloning method, and have 
found it to be a robust approach (data not shown). 
Although, designed for reverse genetics, the influenza 
genome segments cloned into pLLB plasmids could be 
used to express individual influenza viral RNA molecules, 
or for performing in vitro replication assays of mutant 
influenza RNA polymerases in primate cells. The pLLB 
plasmids can also be used to produce proteins in vitro in 
conjunction with T7 RNA polymerase or RNA polymerase 
II -driven systems.     
 
In summary, we describe the construction and use of a pair 
of plasmid DNA vectors, pLLBA and pLLBG, that were 
designed for recombinational cloning of any influenza 
genome segment without the need for enzymatic cloning 
steps aside from RT-PCR synthesis of the viral cDNA. 
The pLLBA and pLLBG vectors were also generated by 
recombination demonstrating the general utility of 
recombination in general genetic modification. The 
general recombineering approach taken in this influenza 
virus reverse genetics system is applicable to the design of  
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reverse genetics systems for other single stranded negative 
sense RNA viruses. For example, the pLLB plasmids 
could be modified for the expression of other segmented 
or non-segmented RNA viruses by replacing the influenza 
cloning cassette with the appropriate terminal promoter 
sites separated by restriction enzyme sites for linearization.  
Additional proteins required for viral replication of some 
single-stranded RNA viruses could be introduced, as 
needed, into the pHP or similar protein expressing 
plasmids. The use of the currently described 
recombinational vectors for 8-plasmid influenza virus 
rescue will facilitate rapid analysis and vaccine production 
of novel influenza strains through the application of 
reverse genetics. 
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